Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study

Blood

Volumn 99, Issue 3, 2002, Pages 863-871

  Annino, Luciana ^a   Vegna, Maria Luce ^a   Camera, Andrea ^a   Specchia, Giorgina ^a   Visani, Giuseppe ^a   Fioritoni, Giuseppe ^a   Ferrara, Felicetto ^a   Peta, Antonio ^a   Ciolli, Stefania ^a   Deplano, Wilma ^a   Fabbiano, Francesco ^a   Sica, Simona ^a   Di Raimondo, Francesco ^a   Cascavilla, Nicola ^a   Tabilio, Antonio ^a   Leoni, Pietro ^a   Invernizzi, Rosangela ^a   Baccarani, Michele ^a   Rotoli, Bruno ^a   Amadori, Sergio ^a   Mandelli, Franco ^a,b   more..

^a GIMEMA Foundation   (Italy)

^b Department of Cellular Biotechnology and Hematology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; DRUG INFUSION; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036464686     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.863     Document Type: Article

References (45)

1. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
2. A causespecific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969
3. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation and maintenance chemotherapy
4. Results of the vincristine, doxorubicin and dexamethasone regimen in adults with acute lymphocytic leukemia
5. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report
6. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811
7. Intensive postremission chemotherapy without maintenance therapy in adult acute lymphoblastic leukemia
8. Estimated 6-year event free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin
9. Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a "pre-induction" course for rapid tumour reduction: Preliminary results on 66 patients
10. Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy
11. Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in first remission
12. Consolidation treatment of adult acute lymphoblastic leukemia: A prospective randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant Interleukin-2 after autologous bone marrow transplantation
13. The GIMEMA ALL 0183 trial: Analysis of 10-year follow up
14. Cytarabine with high-dose mitoxantrone induces rapid complete remission in adult acute lymphoblastic leukemia (ALL) without vincristine or prednisone
15. Prevention of bacterial infection in neutropenic patients with hematologic malignancies: A randomized, multicenter trial comparing norfloxacin with ciprofloxacin
16. The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlation
17. Immunophenotype of acute lymphoblastic leukemia cells: The experience of the Italian Cooperative Group (GIMEMA)
18. Philadelphia (Ph1) positive acute lymphoblastic leukemia (ALL) in adults: Interim analysis of the GIMEMA ALL 0288 pilot study
19. Nonparametric estimation from incomplete observations
20. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: Analysis and examples
21. Nonparametric confidence limits survival probabilities and median survival time
22. Regression models and life-tables
23. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
24. Evidence of an hypercoagulable state in patients with acute lymphoblastic leukemia treated with low-dose E. coli L-asparaginase
25. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows prediction of a favourable treatment outcome
26. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: Durable responses to chemotherapy associated with low initial white blood cell counts
27. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
28. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
29. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
30. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia
31. Use of recombinant human granulocyte colony stimulating factor to increase chemotherapy dose-intensity: A randomized trial in very high-risk childhood acute lymphoblastic leukemia
32. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: Overview of 42 trials involving 1200 randomized children
33. Treatment of adult acute lymphoblastic leukemia
34. New approaches to acute lymphoblastic leukemia in adults: Where do we go?
35. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood
36. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991)
37. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
38. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia
39. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8364
40. Autologous versus unrelated donor allogeneic bone marrow transplantation for acute lymphoblastic leukemia
41. Long-term results of a prospective Belgium-French protocol of treatment for adult acute lymphoblastic leukemia: LALA87 study
42. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR): Early results from international ALL trial (MRC UK ALL/ECOG E2993)
43. Longterm follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation